Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer

NCT03181308 is registered in ClinicalTrials.gov with Tracon Pharmaceuticals Inc. as lead sponsor.

NCT NCT03181308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03181308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer
Lead sponsor
Tracon Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 9, 2017
Completion date
July 22, 2019
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung